Literature DB >> 6225800

C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.

M K Pangburn, R D Schreiber, H J Müller-Eberhard.   

Abstract

Examination of C3b deposition on the surface of activators during alternative pathway activation revealed three temporal phases: a lag phase, an amplification phase, and a heretofore uncharacterized plateau phase. During the plateau phase no C3b deposition appeared to occur even in the presence of an excess of alternative pathway components. Double label experiments, however, revealed that the plateau was a steady state between continued C3b deposition and release of C3b or C3bi from the activator. Under conditions of excess complement it was found that deposition of increasing numbers of C3b molecules caused a gradual increase in the ability of Factors H and I to inactivate newly deposited C3b; i.e., the deposited C3b converted the activator into a nonactivator. The data indicate that the surface of rabbit erythrocytes is rendered completely nonactivating when 2.4 X 10(6) molecules of C3b plus C3bi are bound per cell. The plateau of C3b deposition appears to represent the maximum steady state level maintainable by a given concentration of complement components, and it also reflects conversion of an activating surface to one resembling a nonactivator.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6225800

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Effect of complement-protein-C3b density on the binding of complement factor H to surface-bound C3b.

Authors:  V Koistinen
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

2.  Critical role of C5a in sickle cell disease.

Authors:  Gregory M Vercellotti; Agustin P Dalmasso; Terry R Schaid; Julia Nguyen; Chunsheng Chen; Marna E Ericson; Fuad Abdulla; Trevor Killeen; Margaret A Lindorfer; Ronald P Taylor; John D Belcher
Journal:  Am J Hematol       Date:  2019-01-03       Impact factor: 10.047

Review 3.  Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-07       Impact factor: 3.722

4.  Multi-parametric surface plasmon resonance platform for studying liposome-serum interactions and protein corona formation.

Authors:  Otto K Kari; Tatu Rojalin; Stefano Salmaso; Michela Barattin; Hanna Jarva; Seppo Meri; Marjo Yliperttula; Tapani Viitala; Arto Urtti
Journal:  Drug Deliv Transl Res       Date:  2017-04       Impact factor: 4.617

5.  Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.

Authors:  T C Farries; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

Review 6.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

7.  Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.

Authors:  B J Young; T R Kozel
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

Review 8.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

9.  Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.

Authors:  O F Ramos; G Sármay; E Klein; E Yefenof; J Gergely
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation.

Authors:  A Sahu; T R Kozel; M K Pangburn
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.